



Dear SMA community,

Thank you for your request for information.

Biogen is pleased to share that the National Institute for Health and Care Excellence (NICE) has published guidance recommending nusinersen (12 mg) and the high dose regimen (50/28 mg) for the treatment of 5q spinal muscular atrophy (SMA). The recommendation applies to all symptomatic patient types and to pre-symptomatic individuals in the NHS.

We are delighted by this significant outcome as it expands access to the treatment beyond what was previously available on the NHS. NICE's recommendations will enable clinicians and patients to have access to treatment options that meet their evolving needs.

We wish to wholeheartedly thank the SMA community for their continued engagement in this process. This achievement is testament to the considerable contribution of individuals, families and clinicians who have shared their expertise, lived experience and insights. We are grateful to everyone that has been involved in the process.

The NICE guidance will apply to the NHS in England, Wales and Northern Ireland. In England and Wales, the NHS will routinely fund treatment in line with the NICE guidance from 14 May 2026. We are actively engaging with health authorities in Northern Ireland to enable patient access to treatment in accordance with the guidance in the coming weeks.

In Scotland, we are also in discussion with the relevant health authorities to support patient access to the high dose regimen (50/28 mg) for the treatment of 5q spinal muscular atrophy (SMA).

We look forward to continuing our engagement with the SMA community as the NICE guidance is implemented across the NHS.

With kind regards,

Kylie Bromley

General Manager and Managing Director, Biogen UK & Ireland